Uple24

UNITED STATES PATENT AND TRADEMARK OFFICE

Group Art Unit: 1624

Examiner: Bruck Kifle

Applicant(s): Rosen et. al.

Application No.: 09/960,665

Filed: 9/21/2001

Title: Methods and Compositions for

Degradation and/or Inhibition of HER Family

Tyrosine Kinases

Attorney Docket No.: MSK.P-038-2

Assistant Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Applicants request that the references listed on form PTO 1449, which is attached, be made of record in the US Patent and Trademark Office in the file relating to the abovecaptioned application. Copies of the listed references should be available in the file of the parent case, Serial No.: 09/937,192.

Applicants enclose the fee for submission of this IDS. The Commissioner is authorized to charge any fees due in connection with this paper or credit any overpayment to Deposit Account No. 15-0610.

02/01/2003 MIERKE 00000024 03936885

61 F3:1603

160.00 CP

Respectfully Submitted,

Cert. Under 17 CFE 1.8

This paper and the standards is named herein are being deposited with the standard littles. Postal Service with sufficient postal, as set cass mail and addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on

JAN 2 5 2005

Name Sandra J. Lahmann

Marina T. Larson, Ph.D

Attorney/Agent for Applicant(s)

Reg. No. 32038

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paper ork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB contemporary.

Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)
Sheet 1 of

Complete if Known				
Application Number	09/960,665			
Filing Date	9/21/2001			
First Named Inventor	Rosen et. al.			
Art Unit	1624			
Examiner Name	Bruck Kilfe			
Attorney Docket Number	MSK.P-038-2			

NON PATENT LITERATURE DOCUMENTS						
		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²			
		CHAVANY ET AL., p185erbB2 Binds to GRP94 in Vivo, Journal of Biological Chemistry, Page(s) 4974-4977, Volume 271, Number 9				
		GLONEK, <sup>31</sup> P NMR of Mg-ATP in Dilute Solutions: Complexation and Exchange, Int. J. Biochem, 1992, Page(s) 1533-1559, Volume 24, Number 10				
		HAYSTEAD ET. AL.,γ-Phosphate-linked ATP-Sepharose for the affinity purification of pretein kinases, Eur. J. Biochem., 1993, Page(s) 459-467, Volume 214				
		NECKERS, Effects of Geldanamycin and Other Naturally Occurring Small Molecule Antagonists of Heat Shock Protein 90 on HER2 Protein Expression, Breast Disease, Page(s) 49-59, Volume 11				
		PRODROMOU ET. AL., Identification and Structural Characterization of the ATP/ADP-Binding Site in the Hsp90 Molecular Chaperone, Cell, 07/11/1997, Page(s) 65-75, Volume 90				
		SCHNUR ET AL., erbB-2 Oncogene Inhibition by Geldanaymycin Derivatives: Synthesis, Mechanism of Action, and StructureActivity Relationships, J. Med. Chem., Page(s) 3813-3820, Volume 38				

Signature Considered	Examiner	Date	
	Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.